Holen Sie sich die Stockscreener-App
0.76
1.30%
-0.01
Handel nachbörslich:
.77
0.01
+1.32%
Schlusskurs vom Vortag:
$0.77
Offen:
$0.78
24-Stunden-Volumen:
437.12K
Relative Volume:
0.25
Marktkapitalisierung:
$91.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-225.14M
KGV:
-0.3878
EPS:
-1.96
Netto-Cashflow:
$-192.27M
1W Leistung:
+11.36%
1M Leistung:
+1.89%
6M Leistung:
+86.92%
1J Leistung:
-37.70%
1-Tages-Spanne:
$0.75
$0.7928
1-Wochen-Bereich:
$0.6633
$0.798
52-Wochen-Spanne:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Firmenname
Invivyd Inc
Sektor
Branche
Telefon
(781) 819-0080
Adresse
1601 TRAPELO ROAD, WALTHAM
Vergleichen Sie IVVD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.76 | 81.87M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-26 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Eingeleitet | H.C. Wainwright | Buy |
Invivyd Inc Aktie (IVVD) Neueste Nachrichten
Is Invivyd Inc. a good long term investmentMassive stock growth - jammulinksnews.com
What drives Invivyd Inc. stock priceAccelerated investment success - jammulinksnews.com
What analysts say about Invivyd Inc. stockConsistently exceptional gains - jammulinksnews.com
How Invivyd Inc. stock performs during market volatilityFree Stock Market Swing Trading Strategies - Newser
Invivyd Inc. Stock Analysis and ForecastConsistent triple-digit returns - jammulinksnews.com
Goldman Sachs Shines in Q2 2025 Earnings Call - The Globe and Mail
Why Invivyd Inc. stock attracts strong analyst attentionFree Consultation - Newser
What makes Invivyd Inc. stock price move sharplyFree VIP Investment Strategies - Newser
Why Shares of Nebius Group Are Rocketing Higher Today - The Globe and Mail
Invivyd Launches SPEAR Study for Long COVID Therapy - TipRanks
Invivyd forms research group to study monoclonal antibodies for Long COVID - Investing.com
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome - TradingView
Invivyd (IVVD) Receives Continued 'Buy' Rating from D. Boral Cap - GuruFocus
Invivyd’s (IVVD) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Invivyd’s COVID-19 antibody shows promising safety profile in trial - Investing.com
Invivyd Announces Positive Phase 1/2 Trial Results - TipRanks
Trading Day Triumph: Invivyd Inc (IVVD) Ends at 0.79, a -6.47 Surge/Plunge - DWinneX
COVID’s remaining biotech contenders navigate a dwindling market - Pharma Voice
H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall - Insider Monkey
Invivyd stock target cut to $5 by H.C. Wainwright, retains Buy rating - Investing.com Nigeria
Invivyd (NASDAQ:IVVD) Price Target Lowered to $5.00 at HC Wainwright - Defense World
Invivyd (IVVD) Analyst Rating Update: Price Target Lowered | IVV - GuruFocus
Invivyd (IVVD) Price Target Reduced by H.C. Wainwright Amid Revenue Concerns | IVVD Stock News - GuruFocus
Invivyd (IVVD) Publishes Strong Phase 3 Trial Results for COVID-19 Antibody | IVVD Stock News - GuruFocus
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive S - The Manila Times
Breakthrough COVID-19 Drug PEMGARDA Achieves 84% Protection in First Modern U.S. Phase 3 Trial - Stock Titan
Invivyd’s antibody gains spot in cancer guidelines for COVID-19 PrEP By Investing.com - Investing.com South Africa
Invivyd’s antibody gains spot in cancer guidelines for COVID-19 PrEP - Investing.com Australia
Invivyd's Pemgarda Added to NCCN Guidelines in Oncology for B-Cell Lymphomas - marketscreener.com
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas - The Manila Times
Invivyd (IVVD) Monoclonal Antibody Added to NCCN Guidelines for B-Cell Lymphomas | IVVD Stock News - GuruFocus
Finanzdaten der Invivyd Inc-Aktie (IVVD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):